Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19

20 Jun 2020
Graham SP, McLean RK, Spencer AJ, Belij-Rammerstorfer S, Wright D, Ulaszewska M, Edwards JC, Hayes JWP, Martini V, Thakur N, Conceicao C, Dietrich I, Shelton H, Waters R, Ludi A, Wilsden G, Browning C, Bialy D, Stevenson-Leggett P, Hollinghurst P, Gilbride C, Moffat K, Sharpe H, Allen E, Mioulet V, Chiu C, Newman J, Asfor AS, Burman A, Crossley S, Huo J, Owens RJ, Carroll M, Hammond JA, Tchilian E, Bailey D, Charleston B, Gilbert SC, Tuthill TJ and Lambe T


Clinical development of the COVID-19 vaccine candidate ChAdOx1 nCoV-19, a replication-deficient simian adenoviral vector expressing the full-length SARS-CoV-2 spike (S) protein was initiated in April 2020 following non-human primate studies using a single immunisation. Here, we compared the immunogenicity of one or two doses of ChAdOx1 nCoV-19 in both mice and pigs. Whilst a single dose induced antigen-specific antibody and T cells responses, a booster immunisation enhanced antibody responses, particularly in pigs, with a significant increase in SARS-CoV-2 neutralising titres.